Johnson & Johnson MedTech highlights stroke care pipeline, MIGRAINE study at SNIS 2025
Johnson & Johnson MedTech, a leader in neurovascular care, announced today its upcoming data presentations and onsite activities at the 2025 Society of NeuroInterventional Surgery (SNIS) 22nd Annual Meeting & Fellows Course July 14-17 in Nashville, Tenn. The company will present data underscoring its commitment to advancing science and device performance in neurovascular intervention.
“At SNIS 2025, we’re proud to bring forward clinical evidence and technologies that reflect our long-standing commitment to neurovascular innovation,” said Christian Cuzick, President, Worldwide Neurovascular, Johnson & Johnson MedTech. “This year marks 25 years of TRUFILL ® n-BCA and a decade of NTI, the scientific research arm of Johnson and Johnson MedTech Neurovascular, that works to understand neurovascular disease, which uniquely informs our R&D process. As we celebrate these milestones, we’re excited to preview the next generation of catheters in our Stroke Solutions portfolio with CEREGLIDE™ 42 and CEREGLIDE™ 57, which are designed to help physicians achieve even greater precision and performance in clot retrieval and which will complement our CEREGLIDE Family.”
Featured posters include:
· Feasibility of Middle Meningeal Artery Embolization with TRUFILL® n-BCA for Refractory Chronic Migraine – MIGRAINE Study
o Presenter: Adam Arthur, MD; Semmes Murphey Foundation (Memphis, Tenn.)
o Monday, July 14, 4:03 pm – 4:11 pm
· Liquid Embolic-Related Microcatheter Retention Rates in Neurovascular Disease: A Systematic Review and Meta-Analysis
o Presenter: Ansaar T. Rai, MD; Professor and Chair, Department of Neuroradiology (West Virginia University)
o E-Poster
In addition to its scientific presentations, Johnson & Johnson MedTech will participate in interactive educational forums and events during SNIS, including:
- Fellows Course Hands-on Labs | Thursday, July 17, 5:30-9 p.m.
- The Women in Neurointervention Discussion | Wednesday, July 16, 5:30-7 p.m.
- SLICE Workshop | Tuesday, July 15 / Wednesday, July 16 / and Thursday, July 17
- EVOLVING STROKE CARE TICI 2b OR NOT 2b | Tuesday, July 15, 6:00 PM at Moto, 1120 McGavock St, Nashville.
- Drs. Jagadeesan, Samaniego and Farhat share their experiences with the full J&J MedTech stroke portfolio: featuring CEREGLIDE 71, CEREGLIDE 92 and EMBOTRAP III.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit https://www.jnjmedtech.com/en-US/companies/cerenovus and connect on LinkedIn and X
